GDF11 downregulates FOXP3 in T-cell acute lymphoblastic leukemia-derived cells and associates with restraining aggressiveness
The results position the GDF11 response as a good alternative in the search for new therapeutic options for these diseases.
Authors
- Roxana U. Miranda-Labra (ORCID: https://orcid.org/0000-0001-8249-7257)
- Moises Vergara‐Mendoza (ORCID: https://orcid.org/0000-0003-0511-5600)
- Roberto Lazzarini‐Lechuga (ORCID: https://orcid.org/0000-0003-3537-1576)
- Alejandro Escobedo‐Calvario (ORCID: https://orcid.org/0000-0002-8978-3122)
- Araceli Páez (ORCID: https://orcid.org/0000-0003-4688-8271)
- M. Belén Sánchez-Rodríguez
- Verónica Souza-Arroyo (ORCID: https://orcid.org/0000-0002-3923-6278)
- Leticia Bucio (ORCID: https://orcid.org/0000-0002-6963-2642)
- Luis E. Gómez-Quiroz (ORCID: https://orcid.org/0000-0002-5704-5985)
- Monserrat Gerardo‐Ramírez (ORCID: https://orcid.org/0000-0001-7773-9848)
- María Concepción Gutiérrez‐Ruíz (ORCID: https://orcid.org/0000-0003-0501-7226)
Institutions
- Universidad Autónoma Metropolitana (MX)
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX)
- Instituto Nacional de Cardiologia (BR)
- Instituto Nacional de Cardiología (MX)
Publication Details
- Journal
- Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
- Published
- 2025-01-01
- DOI
- https://doi.org/10.32604/or.2025.064899
- Citations
- 2
- Primary Topic
- Signaling Pathways in Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.61